Related Experiment Videos
EEG changes and seizure exacerbation in young children treated with carbamazepine
Insights
Carbamazepine (CBZ) can worsen seizures in children. New abnormal EEG patterns during CBZ treatment strongly correlate with seizure worsening, indicating potential treatment failure.
Area of Science:
- Pediatric Neurology
- Clinical Neurophysiology
- Pharmacology
Background:
- Carbamazepine (CBZ) is a common antiepileptic drug.
- CBZ has been anecdotally reported to exacerbate certain seizure types in pediatric populations.
- The electroencephalogram (EEG) is crucial for diagnosing and monitoring epilepsy.
Purpose of the Study:
- To investigate the correlation between EEG changes and seizure exacerbation in young children treated with Carbamazepine.
- To identify EEG patterns predictive of treatment response or worsening in pediatric epilepsy patients receiving CBZ.
Main Methods:
- Retrospective study of 59 children under 6 years old treated with CBZ.
- EEG recordings were obtained before and after CBZ initiation.
- Patients were categorized into two groups based on EEG changes: Group I (no significant deterioration) and Group II (significant abnormalities, primarily new generalized discharges).
Main Results:
- 56% of children (Group I) showed no significant EEG deterioration, with 67% achieving good seizure control.
- 44% of children (Group II) developed significant EEG abnormalities, predominantly new generalized spike/polyspike-wave discharges.
- Group II patients had a significantly higher rate of seizure exacerbation (65%) and were more likely to have cryptogenic epilepsy.
Conclusions:
- New generalized paroxysmal discharges on EEG after CBZ initiation are highly correlated with seizure exacerbation and adverse treatment outcomes in young children.
- Absence of significant EEG deterioration during CBZ treatment generally predicts good seizure control.
- EEG monitoring can aid in predicting CBZ efficacy and guiding treatment adjustments in pediatric epilepsy.
Abstract:
Carbamazepine (CBZ) has been reported to exacerbate some seizure types in children. We studied the correlation between CBZ-associated EEG changes and seizure exacerbation in 59 children aged < 6 years treated with CBZ. All patients had EEGs before and after initiation of treatment; initial EEGs were not significantly different among the patients. In 33 children (56%), the subsequent EEGs were either unchanged or improved or demonstrated minor changes (Group I), and excellent to complete seizure control was achieved in 67% of patients. In 26 children (44%), the EEG became significantly more abnormal and was characterized predominantly by new appearance of generalized spike/polyspike-and-wave discharges (group II). The majority of these patients (65%) experienced seizure exacerbation (p < 0.001). For group I, symptomatic partial epilepsy, idiopathic focal epilepsy, and complex febrile seizures were significantly more common; in group II, cryptogenic seizure disorders were more common (p < 0.005). Children in group I were more likely to remain on CBZ or to be weaned from medication after successful treatment, whereas children in group II required additional medication(s) or complete discontinuation of CBZ. Our results suggest that new appearance of generalized paroxysmal discharges after treatment is highly correlated with seizure exacerbation or suboptimal control as well as with adverse outcome. Conversely, absence of significant EEG deterioration on CBZ is usually associated with good seizure control.